Manoli Vourvahis

1.8k total citations · 1 hit paper
55 papers, 1.4k citations indexed

About

Manoli Vourvahis is a scholar working on Infectious Diseases, Oncology and Virology. According to data from OpenAlex, Manoli Vourvahis has authored 55 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 22 papers in Oncology and 17 papers in Virology. Recurrent topics in Manoli Vourvahis's work include HIV/AIDS drug development and treatment (26 papers), Drug Transport and Resistance Mechanisms (19 papers) and HIV Research and Treatment (17 papers). Manoli Vourvahis is often cited by papers focused on HIV/AIDS drug development and treatment (26 papers), Drug Transport and Resistance Mechanisms (19 papers) and HIV Research and Treatment (17 papers). Manoli Vourvahis collaborates with scholars based in United States, United Kingdom and Belgium. Manoli Vourvahis's co-authors include Mohamed Elmeliegy, Cen Guo, Diane D. Wang, Angela D. M. Kashuba, Sylvie Abel, David Back, Erjian Wang, Brian Corrigan, A. David Rodrigues and Bharat Damle and has published in prestigious journals such as Analytical Chemistry, Antimicrobial Agents and Chemotherapy and Pharmaceutical Research.

In The Last Decade

Manoli Vourvahis

53 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies

2020 205 citations Mohamed Elmeliegy, Manoli Vourvahis et al. Clinical Pharmacokinetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manoli Vourvahis United States	21	502	444	334	277	262	55	1.4k
Lisa M. Almond United Kingdom	17	381 0.8×	324 0.7×	327 1.0×	259 0.9×	199 0.8×	34	1.1k
Kimberly K. Adkison United States	21	404 0.8×	606 1.4×	435 1.3×	291 1.1×	309 1.2×	42	1.7k
Tanja Saußele Germany	9	454 0.9×	316 0.7×	606 1.8×	178 0.6×	268 1.0×	13	1.1k
Edward O’Mara United States	21	668 1.3×	268 0.6×	369 1.1×	215 0.8×	149 0.6×	46	1.6k
Julia Blievernicht Germany	10	365 0.7×	510 1.1×	593 1.8×	170 0.6×	212 0.8×	10	1.3k
Rob ter Heine Netherlands	26	727 1.4×	453 1.0×	170 0.5×	281 1.0×	274 1.0×	163	2.2k
John Tjia United Kingdom	17	725 1.4×	203 0.5×	332 1.0×	236 0.9×	452 1.7×	23	1.3k
Bryan A. Ward United States	7	450 0.9×	392 0.9×	677 2.0×	141 0.5×	252 1.0×	8	1.4k
Polina German United States	20	905 1.8×	280 0.6×	174 0.5×	202 0.7×	272 1.0×	36	1.9k
Bradley M. Kerr United States	16	285 0.6×	226 0.5×	375 1.1×	366 1.3×	145 0.6×	24	1.4k

Countries citing papers authored by Manoli Vourvahis

Since Specialization

Citations

This map shows the geographic impact of Manoli Vourvahis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manoli Vourvahis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manoli Vourvahis more than expected).

Fields of papers citing papers by Manoli Vourvahis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manoli Vourvahis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manoli Vourvahis. The network helps show where Manoli Vourvahis may publish in the future.

Co-authorship network of co-authors of Manoli Vourvahis

This figure shows the co-authorship network connecting the top 25 collaborators of Manoli Vourvahis. A scholar is included among the top collaborators of Manoli Vourvahis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manoli Vourvahis. Manoli Vourvahis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Varma, Manthena V. S. & Manoli Vourvahis. (2025). Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor. Clinical Pharmacology & Therapeutics. 117(5). 1175–1178.

Kadar, Eugene P., Christopher L. Holliman, Manoli Vourvahis, & A. David Rodrigues. (2024). Inception and Development of a LC–MS/MS Assay for the Multiplexed Quantitation of Nine Human Drug Transporter Biomarkers. Bioanalysis. 16(6). 347–362. 4 indexed citations

Amin, Neeta B., et al.. (2024). Exposure–response modeling of liver fat imaging endpoints in non‐alcoholic fatty liver disease populations administered ervogastat alone and co‐administered with clesacostat. CPT Pharmacometrics & Systems Pharmacology. 14(2). 317–330.

Qiu, Ruolun, Kari R. Fonseca, Arthur Bergman, et al.. (2023). Study of the ketohexokinase inhibitor PF‐06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and Translational Science. 17(1). e13644–e13644. 1 indexed citations

Wang, Xiaoxing, Vivek S. Purohit, Martin E. Dowty, et al.. (2023). Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes. The Journal of Clinical Pharmacology. 63(7). 784–797. 11 indexed citations

Plotka, Anna, Julia Kaplan, Vivek S. Purohit, et al.. (2023). Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity. Pharmaceutical Research. 40(11). 2639–2651. 3 indexed citations

Amin, Neeta B., Amanda Darekar, Quentin M. Anstee, et al.. (2022). Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. 12(3). e056159–e056159. 40 indexed citations

Elmeliegy, Mohamed, Manoli Vourvahis, Cen Guo, & Diane D. Wang. (2020). Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies. Clinical Pharmacokinetics. 59(6). 699–714. 205 indexed citations breakdown →

Tatham, Lee, Marco Siccardi, Trevor P. Scott, et al.. (2018). Towards a Maraviroc long-acting injectable nanoformulation. European Journal of Pharmaceutics and Biopharmaceutics. 138. 92–98. 21 indexed citations

10.

Tatham, Lee, Marco Siccardi, Trevor P. Scott, et al.. (2018). Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics. 138. 30–36. 20 indexed citations

11.

Vourvahis, Manoli, Rong Wang, Daniel Gruener, et al.. (2012). Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug and Alcohol Dependence. 126(1-2). 183–188. 8 indexed citations

12.

Vourvahis, Manoli, et al.. (2012). The Pharmacokinetics of Lersivirine (UK-453,061) and HIV-1 Protease Inhibitor Coadministration in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(1). 24–32. 4 indexed citations

13.

Mills, Anthony, Donna Mildvan, Daniel Podzamczer, et al.. (2012). Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2). 164–170. 30 indexed citations

14.

Langdon, Grant, et al.. (2011). Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK‐453,061), in healthy adult subjects. British Journal of Clinical Pharmacology. 73(5). 768–775. 11 indexed citations

15.

Dumond, Julie B., Manoli Vourvahis, Nardin Rezk, et al.. (2010). A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical Pharmacology & Therapeutics. 87(6). 735–742. 48 indexed citations

16.

Vourvahis, Manoli, Angus N. R. Nedderman, Ruth Hyland, et al.. (2010). Excretion and Metabolism of Lersivirine (5-{[3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers. Drug Metabolism and Disposition. 38(5). 789–800. 21 indexed citations

17.

Vourvahis, Manoli. (2008). The Effect of UGT2B7 Inhibition on the Steady-State Pharmacokinetics of UK-453,061 after Multiple-Dose Administration in Healthy Male Subjects. 46th Annual Meeting. 1 indexed citations

18.

Schrieber, Sarah J., Zhiming Wen, Manoli Vourvahis, et al.. (2008). The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity. Drug Metabolism and Disposition. 36(9). 1909–1916. 68 indexed citations

19.

Shih, Ted, et al.. (2008). Pharmacogenetics: From Bench Science to the Bedside. Drug Information Journal. 42(5). 503–513. 1 indexed citations

20.

Vourvahis, Manoli & Angela D. M. Kashuba. (2007). Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir‐Enhanced Tipranavir. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(6). 888–909. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact